JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.26 CNY | +0.69% |
|
-1.89% | -18.52% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 830M 115M | Sales 2023 | 854M 118M | Capitalization | 2.95B 408M |
|---|---|---|---|---|---|
| Net income 2022 | 83M 11.48M | Net income 2023 | 94M 13M | EV / Sales 2022 | 3.28 x |
| Net Debt 2022 | 40.44M 5.59M | Net cash position 2023 | 114M 15.76M | EV / Sales 2023 | 3.32 x |
| P/E ratio 2022 |
32.3
x | P/E ratio 2023 |
31.1
x | Employees | 1,678 |
| Yield 2022 |
0.62% | Yield 2023 |
1.68% | Free-Float | 50.92% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.69% | ||
| 1 week | -1.89% | ||
| Current month | +2.69% | ||
| 1 month | +1.82% | ||
| 3 months | +17.48% | ||
| 6 months | -19.42% | ||
| Current year | -18.52% |
1 week
7.14
7.40
1 month
6.637.83
Current year
5.209.58
1 year
5.2010.21
3 years
5.2012.34
5 years
5.2012.34
10 years
5.2026.87
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Min Xie
CEO | Chief Executive Officer | 66 | 08-12-31 |
Jian Tao Bi
DFI | Director of Finance/CFO | 54 | 11-07-31 |
Tie Jun Li
PSD | President | 64 | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Rong Sun
BRD | Director/Board Member | 68 | 22-05-10 |
Yi Sheng Zhang
CHM | Chairman | 68 | 99-12-31 |
Xiao Min Xie
CEO | Chief Executive Officer | 66 | 08-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 7.26 | +0.69% | 3,700,750 |
| 24-05-16 | 7.21 | +0.42% | 3,535,000 |
| 24-05-15 | 7.18 | -1.64% | 5,259,000 |
| 24-05-14 | 7.3 | +0.83% | 9,796,500 |
| 24-05-13 | 7.24 | -2.16% | 6,904,350 |
End-of-day quote Shenzhen S.E., May 16, 2024
More quotes
JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and distribution of Chinese patent drugs for the treatment of cardiovascular and cerebrovascular disease. The Companyâs main products consist of Shengmai injections, Zhenyuan capsules, Xinyue capsules, Qingkailing injections and Guifu Dihuang capsules, among others. The Company's products are applied in the treatment for heart cerebrovascular diseases and detoxification. The company also provides health care products and cosmetics. The Company distributes its products within China market.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.52% | 333M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 002566 Stock
